Searched for
CDMO CONTRACTS
Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplashIndian pharma stocks are outperforming the market, offering strong returns to investors. This resilience is driven by robust domestic deman...- Aurobindo Pharma enters biologics contract manufacturing with Rs 1,200-crore Telangana facilityAurobindo Pharma has launched TheraNym, a major biologics manufacturing plant in Telangana. This facility will produce biologic medicines f...
- AI-linked hiring in CDMO industry jumps nearly 3-fold in 2 years: ReportArtificial intelligence skill demand in India's Contract Development and Manufacturing Organisation sector is set to surge. Demand for AI s...
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...
- Crude awakening: Chemical companies face margin pressure as oil-linked costs surge amid geopolitical tensionsRising crude oil prices are pressuring chemical sector margins due to increased feedstock and energy costs. Despite this, the Nifty Chemica...
- Nifty Pharma, 4 others hit 52-week high since Iran war while Nifty fell 7%. Will the form continue?Despite a challenging market backdrop fueled by geopolitical tensions and foreign fund outflows, five Indian sectors—Pharma, Energy, Defenc...
- Deepa Jewellers, Cotec Healthcare receive Sebi approval for IPOsDeepa Jewellers, a B2B hallmarked gold jewellery processor based in Hyderabad, and Cotec Healthcare, a pharmaceutical CDMO, both received S...
- Nifty stuck in a range but small and midcaps are where real money is being made: Ashish ChaturmohtaIndian stock markets may appear stagnant, but opportunities exist in small and midcap stocks. JM Financial's Ashish Chaturmohta highlights ...
- Cenexi recovery, new product launches and capacity additions power Gland Pharma outlookGland Pharma stock surged to a 52-week high following robust March quarter and full-year results. Its European unit, Cenexi, is improving p...
- Laurus Labs adds Rs 40,150 crore to investors' wealth in a year with 120% rally. Buy, hold or book profits?Laurus Labs has significantly boosted investor wealth, adding over Rs 40,000 crore in a year with a 120% stock rally. Driven by business im...
- Gland Pharma shares jump 11% as Q4 profit soars 97% YoY, co announces Rs 20/share final dividendShares of Gland Pharma rallied on Monday after the company reported a 97% YoY surge in Q4 profit and strong revenue growth, driven by its C...
- Buy the chaos: Why Kashyap Javeri says market volatility is an investor's best friend right nowFund Manager Kashyap Javeri views market corrections as opportunities, not warnings. He advocates for investing during volatility, highligh...
- Earnings season is strong, but Q1 pain is coming: Dipan MehtaMarket expert Dipan Mehta finds India's current earnings season strong. He notes that future quarters will test corporate India due to pote...
- Nandini Piramal warns prolonged West Asia war may raise input costsGeopolitical tensions in West Asia are manageable now. However, a prolonged US-Israel war against Iran could raise costs for petrochemical-...
- Sun Pharma deal: Perception changer for Indian pharma sector? 10 pharma stocks with upside potential of up to 38%The Indian pharma sector made its initial global forays almost a quarter century ago. Companies sought out markets abroad, learnt to deal w...
- Infosys Q4 profit spikes; Flipkart mulls separate app for MinutesInfosys closed FY26 with strong numbers aided by a pickup in demand from its banking, energy and communication segments. This and more in...
- STCH bets on AI to fix trial-and-error in fabric R&D, raises $5.5 million from Omnivore, Kae CapitalSTCH is revolutionizing fabric development with AI. The company helps fashion brands design and source materials efficiently. This platform...
- Why smallcap funds are still a buy: A long-term strategy from Aditya KhemaniSmallcap valuations seem high but underlying fundamentals have improved. Aditya Khemani of Invesco Mutual Fund sees this as a structural sh...
- Share buybacks this month: Wipro, Aurobindo Pharma, 2 other stocks to watch out forFour companies—Wipro, Cyient, Windlas Biotech, and Aurobindo Pharma—are set to announce or act on share buybacks this month, with Aurobindo...
- Axis MF's Sachin Relekar backs consumer internet, financials & metals for long-term gainsSachin Relekar of Axis Mutual Fund sees opportunities in consumer internet, financials, and metals. He believes platform businesses are nea...
Load More
